BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15616152)

  • 1. Metabolism of melatonin by human cytochromes p450.
    Ma X; Idle JR; Krausz KW; Gonzalez FJ
    Drug Metab Dispos; 2005 Apr; 33(4):489-94. PubMed ID: 15616152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro.
    Chang SY; Chen C; Yang Z; Rodrigues AD
    Drug Metab Dispos; 2009 Aug; 37(8):1667-75. PubMed ID: 19454483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin.
    Chang TK; Chen J; Yang G; Yeung EY
    J Pineal Res; 2010 Jan; 48(1):55-64. PubMed ID: 19919601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity.
    Hanna IH; Dawling S; Roodi N; Guengerich FP; Parl FF
    Cancer Res; 2000 Jul; 60(13):3440-4. PubMed ID: 10910054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1.
    Shimada T; Gillam EM; Sutter TR; Strickland PT; Guengerich FP; Yamazaki H
    Drug Metab Dispos; 1997 May; 25(5):617-22. PubMed ID: 9152602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine.
    Yu AM; Idle JR; Krausz KW; Küpfer A; Gonzalez FJ
    J Pharmacol Exp Ther; 2003 Apr; 305(1):315-22. PubMed ID: 12649384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative metabolism of the alkaloid rutaecarpine by human cytochrome P450.
    Ueng YF; Don MJ; Jan WC; Wang SY; Ho LK; Chen CF
    Drug Metab Dispos; 2006 May; 34(5):821-7. PubMed ID: 16501007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of cytochrome P450 isoforms involved in 1-hydroxylation of pyrene.
    Kim YD; Todoroki H; Oyama T; Isse T; Matsumoto A; Yamaguchi T; Kim H; Uchiyama I; Kawamoto T
    Environ Res; 2004 Mar; 94(3):262-6. PubMed ID: 15016593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol.
    Hiratsuka M; Hinai Y; Sasaki T; Konno Y; Imagawa K; Ishikawa M; Mizugaki M
    Drug Metab Dispos; 2007 Oct; 35(10):1730-2. PubMed ID: 17646278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NADPH- and hydroperoxide-supported 17beta-estradiol hydroxylation catalyzed by a variant form (432L, 453S) of human cytochrome P450 1B1.
    Spink DC; Spink BC; Zhuo X; Hussain MM; Gierthy JF; Ding X
    J Steroid Biochem Mol Biol; 2000 Sep; 74(1-2):11-8. PubMed ID: 11074351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1.
    Reid JM; Kuffel MJ; Miller JK; Rios R; Ames MM
    Clin Cancer Res; 1999 Aug; 5(8):2192-7. PubMed ID: 10473105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?
    Rochat B; Morsman JM; Murray GI; Figg WD; McLeod HL
    J Pharmacol Exp Ther; 2001 Feb; 296(2):537-41. PubMed ID: 11160641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
    Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2.
    Chang TK; Chen J; Lee WB
    J Pharmacol Exp Ther; 2001 Dec; 299(3):874-82. PubMed ID: 11714871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling.
    Lo SN; Chang YP; Tsai KC; Chang CY; Wu TS; Ueng YF
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):671-80. PubMed ID: 23886934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A metabolomic perspective of melatonin metabolism in the mouse.
    Ma X; Chen C; Krausz KW; Idle JR; Gonzalez FJ
    Endocrinology; 2008 Apr; 149(4):1869-79. PubMed ID: 18187545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 7H-dibenzo[c,g]carbazole metabolism by the mouse and human CYP1 family of enzymes.
    Shertzer HG; Genter MB; Talaska G; Curran CP; Nebert DW; Dalton TP
    Carcinogenesis; 2007 Jun; 28(6):1371-8. PubMed ID: 17166882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
    Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
    Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
    Thijssen HH; Flinois JP; Beaune PH
    Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preference for
    Nagayoshi H; Murayama N; Tsujino M; Takenaka S; Katahira J; Kim V; Kim D; Komori M; Yamazaki H; Guengerich FP; Shimada T
    Xenobiotica; 2020 Oct; 50(10):1158-1169. PubMed ID: 32312164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.